Cluster and Registry trial Of the Working group of heart failure in Denmark. Are CarvedilOl and Metoprolol succinate comPArable treatments in heart failure patients with Reduced Ejection fraction.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503010-23-01

Acronym

English

Enrollment

5600

Registered

2023-06-16

Start date

2024-03-20

Completion date

Unknown

Last updated

2023-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

The primary endpoint will be a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.

Detailed description

1) All-cause mortality. 2) A combined endpoint of all-cause mortality or first hospitalization for worsening heart failure according to heart rhythm (sinus rhythm or atrial fibrillation/flutter).

Interventions

DRUGMetoprololsuccinat AL 190 mg Retardtabletten

DRUGCarvedilol Mylan 25 mg

DRUGfilmomhulde tabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint will be a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.	—

Secondary

Measure	Time frame
1) All-cause mortality. 2) A combined endpoint of all-cause mortality or first hospitalization for worsening heart failure according to heart rhythm (sinus rhythm or atrial fibrillation/flutter).	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026